Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Oramed'PlatformTech In Oral Delivery Of Proteins Gets Patent In Israel,Australia

Oramed Pharmaceuticals Inc. (ORMP: Quote), a developer of oral drug delivery systems, announced Thursday that it has received Notices of Allowance from the Israel and Australian Patent Offices.

The patent entitled, "Methods and Compositions for Oral Administrations of Proteins" covers a core concept of the company's technology for the oral delivery of drugs and vaccines currently delivered via injection.

The company stated that the allowance in Israel marks the second from the Israel Patent Office in the past 30 days. Additionally, this is Oramed's second Australian patent allowance, following the grant of a different patent in May 2012.

The company noted that the patent has also been approved in Japan, China, Russia, and New Zealand.

Click here to receive FREE breaking news email alerts for Oramed Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.